Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;43(3):284-9.
doi: 10.1007/s12031-010-9436-8. Epub 2010 Aug 20.

Unraveling the role of metal ions and low catalytic activity of cytochrome C oxidase in Alzheimer's disease

Affiliations

Unraveling the role of metal ions and low catalytic activity of cytochrome C oxidase in Alzheimer's disease

Trevor Alleyne et al. J Mol Neurosci. 2011 Mar.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by high levels of aluminum and certain other metal ions in the brain: The disease is also characterized by low activity of brain cytochrome c oxidase (COX) but whether the elevated metal ions and the low COX activity are linked is not known. Moreover, COX is known to exhibit two catalytic rates (V (max)) and two substrate binding constants (K (m)) but it is not known which of these is affected in AD. In this study, we employed the Klatzo AD rabbit model to evaluate the impact of elevated metal ions on brain COX activity. New Zealand white rabbits were injected intra-cerebrally with 1.4% solutions of either AlCl(3), FeCl(3), CaCl(2), or MgCl(2); and 10 days, later the brain mitochondria were isolated. Polarographic assay revealed that compared to the controls, all four metals led to decreases in the V (max) of the enzyme's low affinity site. The respective decreases were; 16%, 36%, 18%, and 30%. The results suggest a sequence of events in vivo in which oxygen radical damage to mitochondria and COX leads to low ATP production and excess heme establishing conditions thought to be ideal for neurodegeneration.

PubMed Disclaimer

References

    1. FASEB J. 2000 Nov;14(14):2198-206 - PubMed
    1. Ann N Y Acad Sci. 2004 Mar;1012:153-63 - PubMed
    1. Curr Alzheimer Res. 2004 Nov;1(4):307-14 - PubMed
    1. Exp Neurol. 2009 Aug;218(2):235-46 - PubMed
    1. FEBS Lett. 1986 Jan 1;194(1):1-5 - PubMed

LinkOut - more resources